Verve Therapeutics Analyst Ratings
Verve Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a reiterated with a price target of $0.00 to $22.00. The current price Verve Therapeutics (VERV) is trading at is $13.07, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2023 | 68.32% | Cantor Fitzgerald | → $22 | Reiterates | Neutral → Neutral |
| 08/15/2023 | 320.81% | Guggenheim | $56 → $55 | Maintains | Buy |
| 08/11/2023 | 137.18% | Credit Suisse | → $31 | Reiterates | Neutral → Neutral |
| 06/16/2023 | 121.88% | Canaccord Genuity | → $29 | Reiterates | Buy → Buy |
| 05/16/2023 | 167.79% | RBC Capital | → $35 | Reiterates | Outperform → Outperform |
| 04/13/2023 | 121.88% | Canaccord Genuity | → $29 | Initiates Coverage On | → Buy |
| 02/01/2023 | 60.67% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Neutral |
| 12/15/2022 | -0.54% | Goldman Sachs | → $13 | Initiates Coverage On | → Sell |
| 11/08/2022 | 167.79% | RBC Capital | $42 → $35 | Maintains | Outperform |
| 10/06/2022 | 267.25% | Credit Suisse | → $48 | Initiates Coverage On | → Neutral |
| 08/25/2022 | 328.46% | Stifel | $32 → $56 | Upgrades | Hold → Buy |
| 07/18/2022 | 374.37% | BMO Capital | $48 → $62 | Maintains | Outperform |
| 06/17/2022 | 267.25% | BMO Capital | → $48 | Initiates Coverage On | → Outperform |
| 02/18/2022 | 221.35% | RBC Capital | → $42 | Initiates Coverage On | → Outperform |
| 09/24/2021 | 343.76% | Stifel | → $58 | Initiates Coverage On | → Hold |
| 07/12/2021 | 603.9% | William Blair | → $92 | Initiates Coverage On | → Outperform |
| 07/12/2021 | 542.69% | Guggenheim | → $84 | Initiates Coverage On | → Buy |
| 07/12/2021 | 282.56% | JP Morgan | → $50 | Initiates Coverage On | → Neutral |
| 07/12/2021 | — | Jefferies | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月29日 | 68.32% | 康託·菲茨傑拉德 | →$22 | 重申 | 中性→中性 |
| 2023年08月15日 | 320.81% | 古根海姆 | $56→$55 | 維護 | 買 |
| 2023年08月11日 | 137.18% | 瑞士信貸 | →$31 | 重申 | 中性→中性 |
| 06/16/2023 | 121.88% | 卡納科特·格納奇 | →$29 | 重申 | 購買→購買 |
| 2023年05月16日 | 167.79% | 加拿大皇家銀行資本 | →$35 | 重申 | 跑贏→跑贏大盤 |
| 04/13/2023 | 121.88% | 卡納科特·格納奇 | →$29 | 開始承保 | →購買 |
| 02/01/2023 | 60.67% | 康託·菲茨傑拉德 | →$21 | 開始承保 | →中性 |
| 2022年12月15日 | -0.54% | 高盛 | →$13 | 開始承保 | →銷售 |
| 11/08/2022 | 167.79% | 加拿大皇家銀行資本 | $42→$35 | 維護 | 跑贏大盤 |
| 10/06/2022 | 267.25% | 瑞士信貸 | →$48 | 開始承保 | →中性 |
| 2022年08月25日 | 328.46% | Stifel | $32→$56 | 升級 | 持有→購買 |
| 07/18/2022 | 374.37% | 蒙特利爾銀行資本 | $48→$62 | 維護 | 跑贏大盤 |
| 06/17/2022 | 267.25% | 蒙特利爾銀行資本 | →$48 | 開始承保 | →跑贏大盤 |
| 02/18/2022 | 221.35% | 加拿大皇家銀行資本 | →$42 | 開始承保 | →跑贏大盤 |
| 09/24/2021 | 343.76% | Stifel | →$58 | 開始承保 | →保留 |
| 07/12/2021 | 603.9% | 威廉·布萊爾 | →$92 | 開始承保 | →跑贏大盤 |
| 07/12/2021 | 542.69% | 古根海姆 | →$84 | 開始承保 | →購買 |
| 07/12/2021 | 282.56% | 摩根大通 | →$50 | 開始承保 | →中性 |
| 07/12/2021 | - | 傑富瑞 | 開始承保 | →購買 |
What is the target price for Verve Therapeutics (VERV)?
Verve Treateutics(VERV)的目標價格是多少？
The latest price target for Verve Therapeutics (NASDAQ: VERV) was reported by Cantor Fitzgerald on August 29, 2023. The analyst firm set a price target for $22.00 expecting VERV to rise to within 12 months (a possible 68.32% upside). 10 analyst firms have reported ratings in the last year.
2023年8月29日，坎託·菲茨傑拉德報道了Verve治療公司(納斯達克：VERV)的最新目標價。這家分析公司將目標價定為22.00美元，預計VERV將在12個月內升至(可能上漲68.32%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Verve Therapeutics (VERV)?
Verve Treateutics(VERV)的最新分析師評級是什麼？
The latest analyst rating for Verve Therapeutics (NASDAQ: VERV) was provided by Cantor Fitzgerald, and Verve Therapeutics reiterated their neutral rating.
對Verve治療公司(納斯達克代碼：VERV)的最新分析師評級是由坎託·菲茨傑拉德提供的，Verve治療公司重申了他們的中性評級。
When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?
Verve治療公司(VERV)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Verve Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Verve治療公司的上一次評級是在2023年8月29日提交的，所以你應該預計下一次評級將在2024年8月29日左右的某個時候提供。
Is the Analyst Rating Verve Therapeutics (VERV) correct?
分析師對Verve Treateutics(VERV)的評級正確嗎？
While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a reiterated with a price target of $0.00 to $22.00. The current price Verve Therapeutics (VERV) is trading at is $13.07, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Verve治療(VERV)評級被重申，目標價在0.00美元至22.00美元之間。Verve Treateutics(VERV)目前的交易價格為13.07美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。
